introduction
The prognosis for patients with Hodgkin's lymphoma (HL) has substantially improved over the last decades. This success is mainly attributed to the introduction and optimization of effective chemotherapy regimens and progress in radiation techniques. With complete remission (CR) rates exceeding 95% and 5-year overall survival (OS) of >80%, aim of prospectively randomized trials has increasingly shifted towards potentially less toxic treatments. One example is the HD8 study of the German Hodgkin Study Group (GHSG) demonstrating that involvedfield radiotherapy (IF-RT) is equally effective when compared with extended-field radiotherapy (EF-RT) after four cycles of chemotherapy for patients with early-stage unfavorable HL [1] .
In contrast to younger patients, in elderly patients with HL the prognosis is still unsatisfactory. Advanced age at presentation is one of the strongest negative risk factors. Different study groups showed significantly poorer outcome for elderly HL patients compared with younger patients when similar treatments were given [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Generally, factors such as more aggressive disease, shorter history of disease, more frequent diagnosis of advanced stage [2] [3] [4] , comorbidity [5] , poor tolerance of treatment [6] , failure to maintain dose intensity [7] [8] [9] [10] , shorter survival after relapse [11, 12] , and death due to other causes [13] contribute to the poorer outcome in elderly patients.
Thus, clinical interest increasingly focuses on this high-risk group of HL patients. A recent comprehensive analysis of GHSG trials' HD5-9 showed that elderly patients present with poorer risk factors, experience more treatment-associated toxicity, receive lower dose intensity, and suffer from higher mortality [14] . Furthermore, intensification of treatment that has been shown to improve outcome for younger HL patients cannot easily be applied to elderly patients. The only prospectively randomized trial in this age group, HD9 elderly for patients with advancedstage HL, reported better tumor control related to intensified chemotherapy which was offset by higher mortality [15] .
Since RT is another key element in the treatment of HL, we revisited the HD8 data for possible differences with regard to the type of RT applied.
patients and methods patients
From February 1993 to March 1998, newly diagnosed patients with biopsyproven HL in clinical stages I and II with selected risk factors as well as patients in clinical stage IIIA without risk factors were enrolled into the GHSG HD8 multicenter trial. Risk factors included the following: (a) large mediastinal mass ( ‡1/3 of maximal thorax diameter, determined by posterior-anterior chest radiography); (b) extranodal disease; (c) massive spleen involvement (diffuse infiltrations or more than five focal lesions); (d) elevated erythrocyte sedimentation rate ( ‡50 mm/h in patients without B symptoms; ‡30 mm/h in patients with B symptoms); or (e) three or more nodal areas involved. All patients with clinical stage IIB with risk factors a, b, or c were allocated to the study for advanced stages.
Patients had to be between 16 and 75 years of age, in good general condition (Karnofsky performance status ‡70%), not previously treated, and free of concurrent infection. Patients with impaired heart, lung, liver, or kidney function; previous malignant disease; or HIV-positive status were not included. Minimal hematological requirements included a WBC count >3000/ll and platelet count >100,000/ll. Patients were also excluded if they were pregnant or lactating. Biopsy material was judged by the local pathologist and then centrally reviewed by at least one member of a panel of six HL expert pathologists. Composite lymphomas were excluded. Routine staging procedures included medical history; physical examination; chest radiography; computed tomography of the chest, abdomen, and pelvis; bone marrow biopsy; skeletal scintigraphy; serum chemistry; lung function tests; and echocardiography. Each patient signed an informed consent form which was based on Institutional Review Board guidelines.
study design
Patients were registered in the HD8 trial and randomly assigned to the two treatment arms as previously described [1] . In arm A, patients received two cycles of COPP/ABVD (COPP alternating with ABVD in every cycle) followed by 30-Gy RT to the EF + 10 Gy to initial bulky disease (single lymph node involvement or conglomerate mass of ‡5 cm in any diameter). In arm B, the same chemotherapy was applied followed by 30-Gy RT to the IF + 10 Gy to initial bulky disease. Additional RT of 10 Gy was given during the fourth week to areas of initial bulky disease. For patients presenting with HL on both sides of the diaphragm, EF-RT was applied in two separate series. Single fraction size was 1.8-2.0 Gy and was given five times a week. EF-RT included the involved lymph node region as well as all anatomic and functionally adjacent but clinically uninvolved lymph node regions. Generally, EF-RT indicated treatment delivered to regions on both sides of the diaphragm. For a supradiaphragmatic involvement, such as the mediastinal nodes, the EF-RT volume included a mantle field and also the para-aortic area (inferior border L4-5 interspace), the splenic hilar region, and the spleen if necessary. The mantle field extended from the inferior portion of the mastoid to the level of the insertion of the diaphragm. Individually contoured lung blocks were designed to conform to the patient's anatomy and tumor extension. The first series of radiation adding up to 16 Gy total were delivered to the initial mediastinal-hilar lymph node enlargement. Subsequently, the mediastinal-hilar contour was modified and included only the extension after chemotherapy. A subdiaphragmatic radiation field was similar to an inverted Y, including the retroperitoneal and pelvic lymph nodes and the spleen. In addition, a mantle field without the upper cervical and axillary region was irradiated (T field). If there was an involvement in the upper cervical region or the Waldeyer's ring only, radiation therapy was administered to supradiaphragmatic regions only. The EF-RT consisted of a mantle field plus additional Waldeyer fields. If only the inguinal nodes were involved, the EF-RT was applied in the inverted-Y technique.
IF-RT was administered to all initially involved lymph node regions. All these regions were treated in one field, if possible, for example a T field for supraclavicular and mediastinal involvement. The procedure for the design of the field contour of bulky mediastinal disease was the same as for EF-RT.
statistical analysis
Response criteria (CR, partial remission, no change, and progressive disease) as well as selection criteria for analysis of acute toxic effects during RT were used as previously described [1] . The Mann-Whitney U test was applied for arm comparisons of acute toxicity (WHO grades 1 to 4); for categorical data, Fisher's exact test was used. Freedom from treatment failure (FFTF) and OS rates were analyzed according to the Kaplan-Meier method [16] . The main end point of the trial was FFTF after the start of RT. FFTF was defined from the start of RT to the first of the following events: progression during RT, lack of CR at the end of protocol treatment, relapse, or death from any cause. The arm comparison for OS was also based on the time calculated from the start of RT until death from any cause or date of last information, respectively. Kaplan-Meier estimates were compared using the log-rank test. A P value <0.05 was considered significant in this explorative retrospective analysis without adjustment for multiplicity. All statistical analyses were carried out with SAS 8.2 (SAS Institute Inc., Cary, NC).
results patient characteristics
A total of 1204 patients were randomly assigned to the two treatment arms. The median observation time was 55 months for both treatment groups. The flow of patients through the various stages of the trial as well as reasons for exclusion and original article Annals of Oncology discontinuation were presented in detail elsewhere [1] . The 1064 patients actually starting RT (informative patients) provide the basis for the current analysis. Of these, 89 patients (8.4%) were 60 years or older and 975 patients were younger than 60 years. Demographic data and the number of patients according to treatment arm are given in Table 1 .
Generally, there were more negative risk factors, such as B symptoms, elevated erythrocyte sedimentation rate, and poorer Karnofsky performance status, in the elderly group. On the other hand, there were fewer large mediastinal masses, a smaller number of lymph node areas involved, and fewer bulky tumors in elderly patients. Younger patients more often presented with nodular sclerosis subtype, whereas the frequency of mixedcellularity subtype was higher in elderly patients. Patient characteristics are shown in Table 2 .
administration of treatment and toxicity
All patients were scheduled to the same initial chemotherapy consisting of two cycles of COPP alternating with two cycles of ABVD. The most commonly observed toxic effects during chemotherapy included WHO grade 3 or 4 leucopenia (71.6% for patients ‡60 years; 56.2% for patients <60 years), alopecia (36.4% for patients ‡60 years; 23.8% for patients <60 years), and nausea (6.8% for patients ‡60 years; 11.1% for patients <60 years) with no difference between study arms. Other acute grade 3 or 4 toxic effects during chemotherapy occurred in <2% of all patients.
Acute toxicity during RT was more pronounced in patients undergoing EF-RT (arm A), including nausea, hematological, pharyngeal, and gastrointestinal (GI) toxicity [1] . A total of 11.3% of all patients had WHO grade 3 or 4 toxicity during RT. Compared with the group of patients younger than 60 years, elderly patients more often suffered from severe toxicity especially those assigned to the EF-RT arm (26.5% in arm A and 8.6% in arm B, P < 0.05). As shown in Table 3 , in elderly patients especially nausea and leucopenia grade 3 and 4 were more pronounced in the EF-RT arm with 3 of 34 (8.8%) versus 0 of 35 in the IF-RT arm.
treatment outcome, causes of death, and secondary malignancies
Response rates, causes of death, and secondary malignancies according to age and treatment are shown in Table 4 . In all, 97.8% of all patients achieved CR or CR unconfirmed, without notable differences with respect to age and treatment modality. In contrast to younger patients, however, more elderly patients died during follow-up. Causes of death included HL, toxicity from primary or salvage treatment, secondary malignancies, and cardiovascular or pulmonary disease. The total number of secondary malignances was 39 (3.7%), with 10 (11.2%) occurring in elderly patients and 29 (3.0%) in younger patients. So far, in elderly patients, there were six secondary malignancies after EF-RT (13.0%) as compared with four after IF-RT (9.3%).
survival
In the current analysis, FFTF and OS was remarkably lower for elderly compared with younger patients: after a median followup of 60 months, the 5-year FFTF was 64% [95% confidence interval (CI) 52% to 76%) in patients ‡60 years and 87% (85% to 90%) in patients <60 years (log-rank, P < 0.001)]. The 5-year OS was 70% (59% to 81%) and 94% (92% to 96%), respectively (log-rank, P < 0.001) as shown in Figure 1 .
Most importantly, elderly patients showed different outcomes according to the type of RT received: patients older than 60 had Annals of Oncology original article a significantly inferior outcome when treated with EF-RT as compared with IF-RT, in terms of both, FFTF (EF: 58%, 42% to 73%; IF: 70%, 52% to 88%; log-rank P = 0.034) and OS (EF: 59%, 44% to 75%; IF: 81%, 67% to 95%; log-rank P = 0.008) (Figure 2 ).
discussion
The objective of the current analysis was to compare toxicity and treatment outcome for elderly and younger HL patients depending on the technique of RT applied (EF or IF). The following results emerge from this study: first, acute toxicity from RT was more pronounced in the group of patients receiving EF-RT. Second, FFTF (64% versus 87%) and OS (70% versus 94%) at 5 years was lower in elderly patients when compared with younger patients receiving identical treatment. Third, elderly patients who were treated in the EF-RT arm had a significantly inferior outcome compared with elderly patients in the IF-RT arm with a difference of 12% for FFTF and 22% for OS after 5 years. Elderly HL patients with early-stage disease and adequate organ function qualify for very similar curative approaches as younger patients. The treatment generally involves combined modality treatment including chemotherapy and RT. Even selected elderly patients, however, have a significantly poorer outcome when compared with younger HL patients due to poorer tolerance of treatment resulting in less dose intensity. Other factors include shorter survival after relapse, more comorbidity, and others [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . A recent GHSG analysis on 373 elderly HL patients ( ‡60 years) demonstrated that higher mortality during treatment as well as lower dose intensity were the major factors explaining the poorer overall outcome of elderly HL patients [14] . In an attempt to improve the poor prognosis for elderly HL patients, the GHSG conducted the HD9 elderly trial in which patients with advanced disease aging 60 years and more were randomized between eight courses of COPP-ABVD or BEACOPP (combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) baseline. The better tumor control achieved with BEACOPP baseline, however, was offset by more toxicity and did not translate into better outcome [15] .
Older age at presentation was also described as negative risk factor in patients undergoing treatment of other malignancies: in a population-based study including 381 patients with aggressive non-Hodgkin's lymphoma (NHL), the proportion of patients who received chemotherapy decreased with older age. There were more patients requiring dose reduction due to comorbidity, poor performance status, or chemotherapy-related original article Annals of Oncology toxicity [17] . Similar factors contributing to a poorer OS in elderly patients were found in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia [18, 19] . Thus, new approaches for elderly patients are warranted. New regimens specifically targeted at elderly HL patients, such as vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin (VEPEMB) [20] , vincristine, doxorubicin, bleomycin, etoposide and prednisone (OBDEP) [21] , bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbacine and prednisone (BACOPP) [22] , and prednisone, vinblastine, doxorubicin and gemcitabine (PVAG) [23] , are currently being evaluated by different study groups. To our knowledge, this is the first report derived from a prospective controlled study identifying significantly more mortality and toxicity in elderly patients when receiving larger field RT. Although combined modality treatment including EF-RT resulted in similar responses as compared with IF-RT, there was significantly poorer OS associated with more toxicity in elderly patients. Radiation-induced effects, including nausea, hematological toxicity, pharyngeal, and GI toxicity, were clearly more often seen in elderly patients undergoing EF-RT. More GI toxicity from EF-RT is due to the larger radiation volume including abdominal regions in patients with supradiaphragmatic involvement only [24] .
The reduction of RT field size seems to be essential in order to reduce long-term sequelae of treatment. Patients undergoing mantle field RT have a higher risk of late cardiac and pulmonary disease [25] [26] [27] . Furthermore, patients who receive large radiation fields, either alone or in combination with chemotherapy more often encounter secondary malignancies, such as AML [28] , NHL [29] , and solid tumors [30] [31] [32] [33] [34] 
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and field size [30] [31] [32] [33] [34] . In the current analysis, 11.2% secondary malignancies occurred in elderly patients and 3.0% in younger patients. Though the numbers were small and the follow-up is still relatively short, there were more secondary malignancies in the EF-RT arm; 13.0% versus 9.3% in elderly and 3.7% versus 2.2% in younger patients. As a consequence from the results of the GHSG HD8 trial and similar data by the European Organisation for Research and Treatment of Cancer (EORTC), IF-RT has become the new standard in combined modality treatment which should reduce acute and long-term toxicity [1, 35] . For elderly patients, current approaches include RT applied to residual lesions only or no RT at all [23] . Whether a further reduction of RT dose is possible while maintaining the excellent results in the whole HL population is subject to recently conducted and ongoing clinical trials. In the GHSG HD11 trial, patients with early unfavorable HL were allocated to four cycles of chemotherapy followed by either 30-or 20-Gy IF-RT. Interim results at 2 years indicate no significant difference in treatment outcome [36] . Similar interim results were observed for early favorable stages in the GHSG HD10 trial [37] . In addition, the H9F trial of the EORTC and Groupe d'Etude des Lymphomes de L'Adulte (GELA) evaluated a possible dose reduction of RT (36 or 20 Gy or no RT) after six cycles of epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy [38] . Here, the arm without RT had to be closed prematurely due to an unexpected high relapse rate. Thus, the use of chemotherapy only in early-stage HL is still experimental. Furthermore, development of new therapeutic approaches such as immunotherapy with monoclonal antibodies associated with less toxicity is urgently needed [39] .
Taken together, our data demonstrate that outcome of patients aged 60 years or older clearly depends on the modality references
